Inventiva Shares Drop 5.87% Midday Amid Consolidation

Short-Term Downtrend Continues

This mid-session correction is part of a short-term downward trend that has been affecting the stock for several weeks. Over the past seven days, Inventiva has seen a decline of 8.12%, amplifying a negative trend that has been in place for three months with a loss of 23.33%. The current price of 3.45 euros thus significantly deviates from the 50-day moving average of 3.84 euros. Paradoxically, this correction does not erase the remarkable annual performance of the stock, which shows an increase of 44.96% since the beginning of the year, significantly outperforming the CAC 40 which has only gained 11.52% over the same period. The movement of the day occurs without any immediate news catalyst. The last major announcement from the company dates back to mid-November, when Inventiva had finalized a fundraising of 172.5 million dollars on the Nasdaq, including the full exercise of the banking option. This operation, intended to finance the continuation of the phase III clinical trial of lanifibranor against MASH, had been carried out at a price of 3.85 dollars per ADS, approximately 3.33 euros per share. The current decline could therefore reflect a post-dilution digestion phase, with investors gradually integrating the impact of the increase in the number of shares in circulation.

Technical Analysis

Technically, the RSI stands at 63, signaling a still favorable dynamic without reaching overheating zones. This indicator suggests that the stock retains some upside potential, despite the recent correction. The Bollinger Bands, positioned between 3.22 euros (lower bound) and 3.85 euros (upper bound), frame the current price which is now in the middle of this channel, after having tested the resistance at 3.77 euros in recent days. The support threshold at 3.04 euros now constitutes a level of vigilance to be monitored in case of a continuation of the downward movement. The positive MACD histogram at 0.02 confirms a fundamentally bullish trend that remains technically intact, the MACD line at 0.06 remaining above the signal line at 0.03. This technical configuration suggests a potential rebound, provided the stock manages to stabilize above its 200-day moving average, established at 3.32 euros and slightly below the current price. The high monthly volatility of 15.68% and the particularly low beta of 0.45 illustrate the typical profile of a biotechnological value in advanced clinical phase, whose movements remain largely decoupled from the general market.

Mixed Cash Flow Indicators

However, cash flow indicators provide more mixed signals. The negative Chaikin Money Flow at -0.11 and the very unfavorable On Balance Volume at -53,705 indicate persistent selling pressure on the stock for several weeks. These data suggest that investors are adopting a cautious stance, likely awaiting the decisive results of the NATiV3 clinical study, whose main results are expected for the second half of 2026. The company's cash horizon, now extended until the end of March 2027 thanks to the recent fundraising, nevertheless eliminates any short-term financing risk and supports Inventiva's ability to carry its flagship clinical program to completion. In this context, the stock fluctuates between technical support and fundamental consolidation, with investors seeking a new balance after the significant dilution in November. The annual performance of nearly 45% reflects the sustained market interest in the potential of lanifibranor for the treatment of MASH, a market estimated between 20 and 35 billion dollars. The trajectory of the stock in the coming weeks will depend on its ability to preserve the support of 3.04 euros and to reconquer the resistance zone of 3.77 euros, in an environment where operational visibility remains conditioned by the progress of clinical trials.